Quantification of HBsAg: Basic virology for clinical practice

World Journal of Gastroenterology

Volumn 17, Issue 3, 2011, Pages 283-289

  Lee, Jung Min ^a   Ahn, Sang Hoon ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Hepatitis B surface antigen; Hepatitis B virus; Quantitative assay; Virology

Indexed keywords

ADEFOVIR; ENTECAVIR; FAMCICLOVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MESSENGER RNA; PEGINTERFERON; PROTEIN S; SPHINGOLIPID ACTIVATOR PROTEIN 2; TELBIVUDINE; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOREACTIVITY; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; OPEN READING FRAME; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; RNA TRANSCRIPTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VACCINATION; VIROLOGY; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

EID: 79955086702     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i3.283     Document Type: Article

References (67)

1. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 1682-1683
2. Ahn SH, Han KH, Park JY, Lee CK, Kang SW, Chon CY Kim YS, Park K, Kim DK, Moon YM. Association betweenhepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000; 31: 1371-1373
3. Kim YS, Park K, Kim DK, Moon YM. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepa-tology 2000; 31: 1371-1373
4. Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-931
5. Thomas HC, Lemon S, Zuckerman AJ. Viral Hepatitis. In: Kann M, Gerlich WH, editors. Structure and molecular virology. 3rd ed. Oxford: Blackwell Publishing, 2005: 149-180
6. Scaglioni PP, Melegari M, Wands JR. Recent advances in the molecular biology of hepatitis B virus. Baillieres Clin Gastro-enterol 1996; 10: 207-225
7. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129
8. Marquardt O, Heermann KH, Seifer M, Gerlich WH. Cell type specifc expression of pre S 1 antigen and secretion of hepatitis B virus surface antigen. Brief Report. Arch Virol 1987; 96: 249-256
9. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984; 52: 396-402
10. Schaller H, Fischer M. Transcriptional control of hepadna-virus gene expression. Curr Top Microbiol Immunol 1991; 168: 21-39
11. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-1631
12. Dienes HP, Gerlich WH, Wörsdörfer M, Gerken G, Bianchi L, Hess G, Meyer zum Büschenfelde KH. Hepatic expression patterns of the large and middle hepatitis B virus surface proteins in viremic and nonviremic chronic hepatitis B. Gastroenterology 1990; 98: 1017-1023
13. Gallina A, De Koning A, Rossi F, Calogero R, Manservigi R, Milanesi G. Translational modulation in hepatitis B virus preS-S open reading frame expression. J Gen Virol 1992; 73 (Pt 1): 139-148
14. Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA 1991; 88: 1059-1063
15. Ueda K, Tsurimoto T, Matsubara K. Three envelope proteins of hepatitis B virus: large S, middle S, and major S proteins needed for the formation of Dane particles. J Virol 1991; 65: 3521-3529
16. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, Palmiter RD, Brinster RL. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 6909-6913
17. Persing DH, Varmus HE, Ganem D. Inhibition of secretion of hepatitis B surface antigen by a related presurface poly-peptide. Science 1986; 234: 1388-1391
18. Pontisso P, Ruvoletto MG, Gerlich WH, Heermann KH, Bar-dini R, Alberti A. Identifcation of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology 1989; 173: 522-530
19. Ishikawa T, Ganem D. The pre-S domain of the large viral envelope protein determines host range in avian hepatitis B viruses. Proc Natl Acad Sci USA 1995; 92: 6259-6263
20. Hertogs K, Leenders WP, Depla E, De Bruin WC, Meheus L, Raymackers J, Moshage H, Yap SH. Endonexin II, present on human liver plasma membranes, is a specifc binding protein of small hepatitis B virus (HBV) envelope protein. Virology 1993; 197: 549-557
21. Ganem D. Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 1991; 168: 61-83
22. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Im-munochemistry 1971; 8: 871-874
23. Wolters G, Kuijpers L, Kacaki J, Schuurs A. Solid-phase enzyme-immunoassay for detection of hepatitis B surfaceantigen. J Clin Pathol 1976; 29: 873-879
24. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsu-chida T, Iinuma K, Mushahwar IK. Quantitation of hepatitis B surface antigen by an automated chemiluminescent mic-roparticle immunoassay. J Virol Methods 2004; 115: 217-222
25. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int 2009; Epub ahead of print
26. Mühlbacher A, Weber B, Bürgisser P, Eiras A, Cabrera J, Louisirirotchanakul S, Tiller FW, Kim HS,Helden J, Bossi V, Echevarria JM. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008; 197: 55-64
27. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004; 44: 1332-1339
28. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 2008; 13: 547-554
29. Chen CH, Lee CM, Wang JH, Tung HD, Hung CH, Lu SN. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol 2004; 16: 1213-1218
30. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE 4th, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758
31. Kohmoto M, Enomoto M, Tamori A, Habu D, Takeda T, Kawada N, Sakaguchi H, Seki S, Shiomi S, Nishiguchi S. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lami-vudine treatment of chronic hepatitis B virus carriers. J Med Virol 2005; 75: 235-239
32. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadzi-yannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HB-sAg levels. Antivir Ther 2007; 12: 73-82
33. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Mar-cellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157
34. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yur-daydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to pe-ginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150
35. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460
36. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepa-tology 2006; 44: 675-684
37. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468
38. Lau G, Marcellin P, Brunetto MR, Piratvisuth T, Kapprell H, Button P, Batrla R. On-treatment HBsAg decline during peginterferon alfa-2a (40KD) ± lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology 2008; 48: 714A
39. Marcellin P, Brunetto MR, Bonino F, Hadziyannis E, Kap-prell H, McCloud P, Batrla R. In patients with HBeAg-neg-ative chronic hepatitis B HBsAg serum levels early during treatment with peginterferon alfa-2a predict HBsAg clearance 4 years post-treatment. Hepatology 2008; 48: 718A
40. Lu L, Ye D, Wang Y, Kwok A, Wong A, Yueng Y, Zhang H, Chen Y, Bowden S, Batrla-Utermann R, Locarnini S, Lau G. Correlation between HBV cccDNA and HBsAg levels and their reduction by peginterferon alfa-2a based therapy in patients with chronic hepatitis B. Hepatology 2008; 48: 746A
41. Bruss V, Ganem D. Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J Virol 1991; 65: 3813-3820
42. Meyer M, Caselmann WH, Schlüter V, Schreck R, Hofsch-neider PH, Baeuerle PA. Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by an-tioxidants and integral membrane localization. EMBO J 1992; 11: 2991-3001
43. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402
44. Mimms L. Hepatitis B virus escape mutants: pushing the envelope of chronic hepatitis B virus infection. Hepatology 1995; 21: 884-887
45. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-329
46. Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003; 60: 75-78
47. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53: 1499-1503
48. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805-816
49. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vier-ling JM, Lok AS. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-222
50. Torresi J. The virological and clinical signifcance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 2002; 25: 97-106
51. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos-(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.e1-e2
52. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T, Jackson DC. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293: 305-313
53. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31: 1318-1326
54. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profle of viral rebound. Hepatology 2008; 48: 88-98
55. Sloan RD, Ijaz S, Moore PL, Harrison TJ, Teo CG, Tedder RS. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 2008; 13: 439-447
56. Kamili S, Sozzi V, Thompson G, Campbell K, Walker CM, Locarnini S, Krawczynski K. Effcacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009; 49: 1483-1491
57. Melegari M, Scaglioni PP, Wands JR. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol 1997; 71: 5449-5454
58. Sengupta S, Rehman S, Durgapal H, Acharya SK, Panda SK. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol 2007; 79: 220-228
59. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. Mutation of the a determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol 2004; 17: 440-444
60. Gerlich WH. Diagnostic problems caused by HBsAg mu-tants-a consensus report of an expert meeting. Intervirology 2004; 47: 310-313
61. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170
62. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999; 59: 19-24
63. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662
64. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242
65. Lee JM, Park JY, Ahn SH, Kim DY, Chon CY, Kim HS, Han KH. Clinical applicability of HBsAg titer in chronic hepatitis B patients with undetectable HBV DNA by real-time PCR assay. Hepatology 2009; 50: 517A
66. Brunetto MR, Bonino F, Marcellin P, Button P, Batrla R. Kinetics of HBsAg decline in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a according to genotype and its association with sustained HBsAg clearance 4 years post-treatment. Hepatology 2008; 48: 740A
67. Hou J, Sun J, Xie Q, Li X, Zhang J, Wang Y, Lai J, Chen S, Jia J, Sheng J, Chan H, Wang J, Jiang M, Popescu M, Sung J. Eff-cacy and safety of peginterferon alfa-2a versus adefovir dip-ivoxil (ADV) in treating lamivudine resistant HBeAg positive CHB: An interim analysis of a prospective randomised study. Hepatology 2008; 43: 745A